Drugs / Zinc-64 Aspartate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06506643 | May 2024 → Jul 2026 overdue | cancer, chronic lymphocytic leukemia/small lymphocytic lymphoma | Vector Vitale LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zinc-64 Aspartate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06506643 ↗ |
| Known as | Zinc Aspartate | “KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc.” NCT06506643 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusions” NCT06506643 ↗ |